Uy Ear
Stock Analyst at Mizuho
(3.01)
# 1,359
Out of 4,876 analysts
63
Total ratings
40.54%
Success rate
13.41%
Average return
Main Sectors:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Outperform | $85 → $40 | $17.11 | +133.78% | 6 | Jun 18, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $20 → $23 | $22.12 | +3.98% | 11 | May 19, 2025 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $51 → $85 | $19.80 | +329.29% | 2 | May 15, 2025 | |
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $20 → $21 | $13.74 | +52.84% | 14 | Feb 26, 2025 | |
| QURE uniQure | Maintains: Neutral | $7 → $20 | $13.86 | +44.30% | 4 | Dec 19, 2024 | |
| RLMD Relmada Therapeutics | Downgrades: Neutral | $23 → $1 | $0.62 | +60.95% | 1 | Dec 5, 2024 | |
| ALKS Alkermes | Maintains: Outperform | $35 → $40 | $28.81 | +38.84% | 5 | Nov 13, 2024 | |
| SAGE Sage Therapeutics | Maintains: Neutral | $18 → $16 | $9.14 | +75.05% | 2 | Jul 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $40 | $10.68 | +274.53% | 1 | May 24, 2024 | |
| EOLS Evolus | Maintains: Buy | $20 → $23 | $9.14 | +151.78% | 3 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $116 → $140 | $125.42 | +11.62% | 10 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $40 | $152.41 | -73.76% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $1.57 | +536.94% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $3 | $0.98 | +204.85% | 2 | Mar 1, 2023 |
Sarepta Therapeutics
Jun 18, 2025
Maintains: Outperform
Price Target: $85 → $40
Current: $17.11
Upside: +133.78%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Neutral
Price Target: $20 → $23
Current: $22.12
Upside: +3.98%
Tectonic Therapeutic
May 15, 2025
Maintains: Outperform
Price Target: $51 → $85
Current: $19.80
Upside: +329.29%
Arcutis Biotherapeutics
Feb 26, 2025
Maintains: Outperform
Price Target: $20 → $21
Current: $13.74
Upside: +52.84%
uniQure
Dec 19, 2024
Maintains: Neutral
Price Target: $7 → $20
Current: $13.86
Upside: +44.30%
Relmada Therapeutics
Dec 5, 2024
Downgrades: Neutral
Price Target: $23 → $1
Current: $0.62
Upside: +60.95%
Alkermes
Nov 13, 2024
Maintains: Outperform
Price Target: $35 → $40
Current: $28.81
Upside: +38.84%
Sage Therapeutics
Jul 19, 2024
Maintains: Neutral
Price Target: $18 → $16
Current: $9.14
Upside: +75.05%
Cartesian Therapeutics
May 24, 2024
Initiates: Buy
Price Target: $40
Current: $10.68
Upside: +274.53%
Evolus
Mar 8, 2024
Maintains: Buy
Price Target: $20 → $23
Current: $9.14
Upside: +151.78%
Feb 8, 2024
Maintains: Neutral
Price Target: $116 → $140
Current: $125.42
Upside: +11.62%
Jun 7, 2023
Maintains: Buy
Price Target: $36 → $40
Current: $152.41
Upside: -73.76%
Mar 17, 2023
Reiterates: Buy
Price Target: $10
Current: $1.57
Upside: +536.94%
Mar 1, 2023
Maintains: Buy
Price Target: $5 → $3
Current: $0.98
Upside: +204.85%